MA46889A - Inhibiteurs de gsk-3 - Google Patents
Inhibiteurs de gsk-3Info
- Publication number
- MA46889A MA46889A MA046889A MA46889A MA46889A MA 46889 A MA46889 A MA 46889A MA 046889 A MA046889 A MA 046889A MA 46889 A MA46889 A MA 46889A MA 46889 A MA46889 A MA 46889A
- Authority
- MA
- Morocco
- Prior art keywords
- gsk
- inhibitors
- Prior art date
Links
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 title 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426631P | 2016-11-28 | 2016-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46889A true MA46889A (fr) | 2019-10-02 |
Family
ID=60655130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046889A MA46889A (fr) | 2016-11-28 | 2017-11-27 | Inhibiteurs de gsk-3 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10752609B2 (https=) |
| EP (1) | EP3544613B1 (https=) |
| JP (1) | JP7114591B2 (https=) |
| KR (1) | KR102575990B1 (https=) |
| CN (1) | CN110545817B (https=) |
| ES (1) | ES2878078T3 (https=) |
| MA (1) | MA46889A (https=) |
| WO (1) | WO2018098412A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2850773T3 (es) * | 2016-11-28 | 2021-08-31 | Bristol Myers Squibb Co | Piridincarboxamidas como inhibidores de GSK-3 |
| WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| EP3898616B1 (en) * | 2018-12-20 | 2024-10-02 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| JP7676308B2 (ja) | 2018-12-20 | 2025-05-14 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド |
| US12540129B2 (en) | 2019-08-02 | 2026-02-03 | Amgen Inc. | KIF18A inhibitors |
| WO2021026099A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| CN116178281B (zh) * | 2023-04-27 | 2023-07-21 | 中国药科大学 | 一种双功能免疫抑制剂及其制备方法和应用 |
| EP4709712A1 (en) * | 2023-05-10 | 2026-03-18 | Blueprint Medicines Corporation | Gsk3a inhibitors and methods of use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102438D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| JP5241834B2 (ja) * | 2007-07-19 | 2013-07-17 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼ阻害剤としての複素環アミド化合物 |
| WO2012024179A1 (en) * | 2010-08-18 | 2012-02-23 | Merck Sharp & Dohme Corp. | Substituted amide derivatives as dgat-1 inhibitors |
| CN105849098A (zh) * | 2013-11-06 | 2016-08-10 | 百时美施贵宝公司 | Gsk-3抑制剂 |
| CN105849097A (zh) | 2013-11-06 | 2016-08-10 | 百时美施贵宝公司 | 取代的吡啶衍生物用作gsk-3抑制剂 |
| WO2016144792A1 (en) * | 2015-03-06 | 2016-09-15 | Alpharmagen, Llc | Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
| ES2850773T3 (es) | 2016-11-28 | 2021-08-31 | Bristol Myers Squibb Co | Piridincarboxamidas como inhibidores de GSK-3 |
-
2017
- 2017-11-27 CN CN201780084344.7A patent/CN110545817B/zh active Active
- 2017-11-27 KR KR1020197018285A patent/KR102575990B1/ko active Active
- 2017-11-27 JP JP2019528512A patent/JP7114591B2/ja active Active
- 2017-11-27 WO PCT/US2017/063231 patent/WO2018098412A1/en not_active Ceased
- 2017-11-27 EP EP17812188.5A patent/EP3544613B1/en active Active
- 2017-11-27 MA MA046889A patent/MA46889A/fr unknown
- 2017-11-27 US US16/463,467 patent/US10752609B2/en active Active
- 2017-11-27 ES ES17812188T patent/ES2878078T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190085114A (ko) | 2019-07-17 |
| ES2878078T3 (es) | 2021-11-18 |
| CN110545817B (zh) | 2022-11-15 |
| JP2019535788A (ja) | 2019-12-12 |
| US10752609B2 (en) | 2020-08-25 |
| CN110545817A (zh) | 2019-12-06 |
| WO2018098412A1 (en) | 2018-05-31 |
| JP7114591B2 (ja) | 2022-08-08 |
| US20190315714A1 (en) | 2019-10-17 |
| EP3544613A1 (en) | 2019-10-02 |
| KR102575990B1 (ko) | 2023-09-08 |
| EP3544613B1 (en) | 2021-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263586A (en) | Inhibitors of the menin-mll interaction | |
| IL269196A (en) | Novel inhibitors | |
| EP3541932A4 (en) | INHIBITORS OF CRISPR-CAS9 | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| DK3442972T3 (da) | Bromdomænehæmmere | |
| LT3303334T (lt) | Tirozinkinazės inhibitoriai | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| EP3347008A4 (en) | BETA-Lactamase INHIBITORS | |
| HUE042335T2 (hu) | ROR-gamma dihidropirrolopiridin inhibitorai | |
| CU20160125A7 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| MA53944A (fr) | Inhibiteurs de la glycosidase | |
| EP3313828A4 (en) | METALLO-BETA-Lactamase INHIBITORS | |
| MA46855A (fr) | Inhibiteurs de magl | |
| MA46857A (fr) | Inhibiteurs de magl | |
| EP3541822A4 (en) | MAGL INHIBITORS | |
| DK3335532T3 (da) | Tandharve | |
| DK3186242T3 (da) | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| MA46889A (fr) | Inhibiteurs de gsk-3 | |
| MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| DK3114120T3 (da) | Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere | |
| MA46280A (fr) | Inhibiteurs de la dopamine-b-hydroxylase | |
| EP3600301A4 (en) | KDM4 INHIBITORS | |
| DK3481826T3 (da) | Tyrosinkinaseinhibitorer | |
| EP3519429A4 (en) | BACTERIAL INHIBITORS |